Clinipace’s Technology-Driven Service Model and Global Experience Driving Greater Trial Visibility, Project Control, and Lower Costs
MORRISVILLE, N.C. (Business Wire) January 12, 2010 — Clinipace Worldwide, a global technology-driven clinical research organization (CRO), announced today that NitricBio has selected the company to manage and deploy multiple studies in support of medical applications of topical nitric oxide gas (gNO).
NitricBio is a mid-stage specialty pharmaceutical company focused on the dermatology and podiatry markets, with two unique drug delivery technologies. The company awarded Clinipace Worldwide a four-project engagement, including data management, statistical services, and medical writing for two phase 2 trials as well as providing fully-integrated clinical research services to manage and conduct two phase 3 trials.
“Clinipace Worldwide offered the global experience and full-service expertise we were looking for in a CRO partner,” said Tanya Rhodes, chief technology officer, NitricBio. “Their approach towards a fully-integrated technology-driven clinical research model will help us drive greater trial visibility, more project control, and, ultimately, lower costs for each of our four trials.”
In addition to delivering clinical development services, Clinipace Worldwide will deploy its web-based technology platform to collect, manage, and monitor study data, which will greatly streamline associated processes and trial timelines for NitricBio.
“Clinipace Worldwide is committed to providing innovative companies like NitricBio with a full-range of development solutions and expert services to match any size clinical study and operational approach,” said Christopher Porter, chief operating officer, Clinipace.
About NitricBio, Inc.
NitricBio is a venture-backed biopharmaceutical and medical device company developing treatments for the healing of chronic wounds and the resolution of infections using topical application of nitric oxide gas (gNO). Nitric oxide has significant broad spectrum antimicrobial effects, including potent effects against drug-resistant bacterial strains, as well as effects on inflammation, collagen production and blood flow. Nitric Bio is pursuing human clinical work in a number of indications as an anti-infective agent for treating or preventing fungal, bacterial and parasitic infections. More information on the company can be found at www.nitricbio.com
Clinipace, an experienced digital clinical research organization (dCRO), provides on-demand software and clinical services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. We serve biopharmaceutical and medical device companies as well as academic medical centers. Optimized by TEMPO™, our web-based software platform, we deliver clinical trial and registry services at up to a 30% savings compared to traditional service providers. Learn more at http://www.clinipace.com.